This company listing is no longer active
Resumen de acción BDXB
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Competidores de Becton, Dickinson and Company
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.16 |
| 52 Week High | US$52.52 |
| 52 Week Low | US$45.85 |
| Beta | 0.56 |
| 1 Month Change | -4.54% |
| 3 Month Change | -0.84% |
| 1 Year Change | -5.73% |
| 3 Year Change | -7.12% |
| 5 Year Change | n/a |
| Change since IPO | -4.63% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| BDXB | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -0.7% | 1.8% | 3.3% |
| 1Y | -5.7% | 0.6% | 25.8% |
Rentabilidad vs. Industria: BDXB underperformed the US Medical Equipment industry which returned 1.1% over the past year.
Rentabilidad vs. Mercado: BDXB underperformed the US Market which returned -1% over the past year.
Volatilidad de los precios
| BDXB volatility | |
|---|---|
| BDXB Average Weekly Movement | 1.3% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: BDXB has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: BDXB's weekly volatility (1%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1897 | 77,000 | Tom Polen | www.bd.com |
Resumen de fundamentos de Becton, Dickinson and Company
| Estadísticas fundamentales de BDXB | |
|---|---|
| Capitalización bursátil | US$70.47b |
| Beneficios(TTM) | US$1.56b |
| Ingresos (TTM) | US$18.81b |
45.3x
Ratio precio-beneficio (PE)3.7x
Ratio precio-ventas (PS)¿Está BDXB sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BDXB | |
|---|---|
| Ingresos | US$18.81b |
| Coste de los ingresos | US$10.21b |
| Beneficio bruto | US$8.60b |
| Otros gastos | US$7.04b |
| Beneficios | US$1.56b |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 5.48 |
| Margen bruto | 45.70% |
| Margen de beneficio neto | 8.27% |
| Ratio deuda/patrimonio | 70.9% |
¿Cómo se ha desempeñado BDXB a largo plazo?
Ver rendimiento histórico y comparativa